Viatris (@viatrisinc) 's Twitter Profile
Viatris

@viatrisinc

We empower people to live healthier at every stage of life. $VTRS

ID: 1194077572046438400

linkhttps://www.viatris.com/en calendar_today12-11-2019 02:21:08

756 Tweet

8,8K Takipçi

172 Takip Edilen

Viatris (@viatrisinc) 's Twitter Profile Photo

Today we announced top-line results from our Phase 3, LYNX-2 Trial in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions. Read for more information here: bit.ly/3Hgf1w7

Viatris (@viatrisinc) 's Twitter Profile Photo

Today we announced positive top-line results from our second pivotal Phase 3 VEGA-3 Trial in presbyopia. Read for more information here: viatr.is/4k6uQTx

Viatris (@viatrisinc) 's Twitter Profile Photo

Today we provided an update on the Phase 3 Study of MR-139 for Blepharitis. Read more information here: viatr.is/4nWJUGB

Viatris (@viatrisinc) 's Twitter Profile Photo

We are celebrating a big win by #TeamCongress at last week’s CWSoftballGame! In addition to bringing together bipartisan lawmakers and members of the press corps, this game supports Young Survival Coalition in its mission to address the unique needs of young adults affected by breast cancer.

We are celebrating a big win by #TeamCongress at last week’s <a href="/CWSoftballGame/">CWSoftballGame</a>! In addition to bringing together bipartisan lawmakers and members of the press corps, this game supports <a href="/YSCBuzz/">Young Survival Coalition</a> in its mission to address the unique needs of young adults affected by breast cancer.
Viatris (@viatrisinc) 's Twitter Profile Photo

Today we announced that five abstracts from our Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference. Learn more: viatr.is/4fj8X2O

Today we announced that five abstracts from our Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference. 

Learn more: viatr.is/4fj8X2O
Viatris (@viatrisinc) 's Twitter Profile Photo

$VTRS reports second quarter 2025 results and reiterates 2025 financial guidance. Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to fwd-looking statements. viatr.is/4liY42q

Viatris (@viatrisinc) 's Twitter Profile Photo

Today we announced the FDA approval of the first generic iron replacement product to treat iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD),helping facilitate increased access to this complex injectable product. Information here: viatr.is/3HqqpG1

Viatris (@viatrisinc) 's Twitter Profile Photo

We are here in Madrid at the #ESCCongress. Visit us at booth A200 to learn more about our efforts in reducing the burden of cardiovascular diseases and the latest on the SOS-AMI trial. #ESCCongress #WCCardio

We are here in Madrid at the #ESCCongress. Visit us at booth A200 to learn more about our efforts in reducing the burden of cardiovascular diseases and the latest on the SOS-AMI trial.

#ESCCongress #WCCardio
Viatris (@viatrisinc) 's Twitter Profile Photo

Visit booth A200 at the #ESCCongress in Madrid to watch the premiere of a film we created with BBC StoryWorks dedicated to raising awareness on the importance of early detection of heart attack symptoms. Look for the full video later this month. #ESCCongress #WCCardio

Viatris (@viatrisinc) 's Twitter Profile Photo

Our team is on site at #PAINWeek2025, stop by to learn more about our efforts in addressing acute and chronic pain, and our Phase 3 program evaluating our investigational asset in moderate-to-severe acute surgical pain models. Read to learn more: viatr.is/3HKVVyL

Viatris (@viatrisinc) 's Twitter Profile Photo

This week we join global experts at #APLAR2025 to advance care for people with systemic lupus erythematosus (SLE), where our team will present insights from the Phase 2 CARE study—underscoring our commitment to addressing unmet medical need in SLE.

This week we join global experts at #APLAR2025 to advance care for people with systemic lupus erythematosus (SLE), where our team will present insights from the Phase 2 CARE study—underscoring our commitment to addressing unmet medical need in SLE.
Viatris (@viatrisinc) 's Twitter Profile Photo

At #PAINWeek2025, we presented 5 abstracts from our Phase 3 program evaluating our investigational asset in moderate-to-severe acute surgical pain models, which further highlighted positive results from two previously announced Phase 3 studies. Learn more: viatr.is/4nh4KPS

At #PAINWeek2025, we presented 5 abstracts from our Phase 3 program evaluating our investigational asset in moderate-to-severe acute surgical pain models, which further highlighted positive results from two previously announced Phase 3 studies. Learn more: viatr.is/4nh4KPS
Viatris (@viatrisinc) 's Twitter Profile Photo

We have been named to Forbes’ list of the World’s Best Employers for the 5th year in a row! Learn more about our culture that prioritizes wellbeing, promotes inclusivity, offers training, learning and development opportunities, and enables high performance viatris.com/careers

We have been named to Forbes’ list of the World’s Best Employers for the 5th year in a row! Learn more about our culture that prioritizes wellbeing, promotes inclusivity, offers training, learning and development opportunities, and enables high performance viatris.com/careers
Viatris (@viatrisinc) 's Twitter Profile Photo

At the #AAOpt Congress, results from our Phase 3 LYNX-2 trial were presented highlighting our investigational asset being evaluated in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions. Read more: viatr.is/4oidS7h

At the #AAOpt Congress, results from our Phase 3 LYNX-2 trial were presented highlighting our investigational asset being evaluated in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions.

Read more: viatr.is/4oidS7h
Viatris (@viatrisinc) 's Twitter Profile Photo

$VTRS completes acquisition of Aculys Pharma including exclusive rights to pitolisant in Japan and to Spydia® in Japan and certain other markets in the Asia-Pacific region. Read more: viatr.is/46Uo68e

Viatris (@viatrisinc) 's Twitter Profile Photo

We are in Chicago at #ACRConvergence2025! Visit our team onsite to learn more about our efforts in systemic lupus erythematosus research, including OPUS, our ongoing global Phase 3 clinical trial program.

Viatris (@viatrisinc) 's Twitter Profile Photo

Today we reported third quarter 2025 results and updated our 2025 financial guidance. $VTRS Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to fwd-looking statements. newsroom.viatris.com/2025-11-06-Via…

Viatris (@viatrisinc) 's Twitter Profile Photo

Recently, our team attended #AHA25 Scientific Sessions. Through our interactive booth and live discussions, we were able to share information about our SOS-AMI trial and overall progress in advancing solutions to improve cardiovascular health for patients worldwide.

Recently, our team attended #AHA25 Scientific Sessions. Through our interactive booth and live discussions, we were able to share information about our SOS-AMI trial and overall progress in advancing solutions to improve cardiovascular health for patients worldwide.
Viatris (@viatrisinc) 's Twitter Profile Photo

We’re proud to share that Viatris has been named to the Fortune World’s Best Workplaces 2025—recognized among just 25 global companies! Learn more about our culture that supports wellbeing and embraces the diverse perspectives of our colleagues worldwide. viatris.com/careers

Viatris (@viatrisinc) 's Twitter Profile Photo

Today we announced four regulatory milestones spanning all stages of our global pipeline, culminating a year of significant R&D advancement. Read for more information here: newsroom.viatris.com/2025-12-18-Via…